Generation and characterization of a preventive and therapeutic HPV DNA vaccine

Vaccine

Volumn 26, Issue 3, 2008, Pages 351-360

  Kim, Daejin ^a,b   Gambhira, Ratish ^a   Karanam, Balasubramanyam ^a   Monie, Archana ^a   Hung, Chien Fu ^a   Roden, Richard ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Chung Ang University   (South Korea)

Author keywords

DNA vaccine; E6; E7; HPV; L2

Indexed keywords

CALRETICULIN; NEUTRALIZING ANTIBODY; PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UTERINE CERVIX CANCER; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; BIOLISTICS; CALRETICULIN; CAPSID PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; DRUG DESIGN; FEMALE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; TUMOR VIRUS INFECTIONS; VACCINES, DNA;

EID: 37549066302     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.019     Document Type: Article

References (36)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
2. Ho G.Y., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13 1 (2004) 110-116
3. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
4. Ferenczy A., and Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 3 1 (2002) 11-16
5. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 5 (2002) 342-350
6. Roden R.B., Yutzy WHt, Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 2 (2000) 254-257
7. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
8. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu Rev Immunol 15 (1997) 617-648
9. Seder R.A., and Gurunathan S. DNA vaccines-designer vaccines for the 21st century. New Engl J Med 341 4 (1999) 277-278
10. Nash P.D., Opas M., and Michalak M. Calreticulin: not just another calcium-binding protein. Molec Cell Biochem 135 1 (1994) 71-78
11. Basu S., Srivastava P.K., and Calreticulin. a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 189 5 (1999) 797-802
12. Conway E.M., Liu L., Nowakowski B., Steiner-Mosonyi M., Ribeiro S.P., and Michalak M. Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J Biol Chem 270 28 (1995) 17011-17016
13. Spee P., and Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 27 9 (1997) 2441-2449
14. Sadasivan B., Lehner P.J., Ortmann B., Spies T., and Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5 2 (1996) 103-114
15. Peng S., Ji H., Trimble C., He L., Tsai Y.C., Yeatermeyer J., et al. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78 16 (2004) 8468-8476
16. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108 5 (2001) 669-678
17. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78 9 (2004) 4638-4645
18. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19 27 (2001) 3652-3660
19. de Jong A., O'Neill T., Khan A.Y., Kwappenberg K.M., Chisholm S.E., Whittle N.R., et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20 29/30 (2002) 3456-3464
20. Gambhira R., Gravitt P.E., Bossis I., Stern P.L., Viscidi R.P., and Roden R.B. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66 23 (2006) 11120-11124
21. Leder C., Kleinschmidt J.A., Wiethe C., and Muller M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75 19 (2001) 9201-9209
22. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
23. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60 4 (2000) 1035-1042
24. Hung C.F., Cheng W.F., Hsu K.F., Chai C.Y., He L., Ling M., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61 9 (2001) 3698-3703
25. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 9 (1993) 2242-2249
26. Ji H., Wang T.-L., Chen C.-H., Hung C.-F., Pai S., Lin K.-Y., et al. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Human Gene Ther 10 17 (1999) 2727-2740
27. Gambhira R., Jagu S., Karanam B., Gravitt P.E., Culp T.D., Christensen N.D., et al. Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2. J Virol 81 21 (2007) 11585-11592
28. Cheng W.F., Hung C.H., Chai C.Y., Hsu K.F., He L., Ling M., et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 75 5 (2001) 2368-2376
29. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78 2 (2004) 751-757
30. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 2 (2004) 205-216
31. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 2 (2005) 365-372
32. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20 54 (2001) 7888-7898
33. Gao Q., Singh L., Kumar A., Srinivasan S., Wazer D.E., and Band V. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. J Virol 75 9 (2001) 4459-4466
34. Dalal S., Gao Q., Androphy E.J., and Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol 70 2 (1996) 683-688
35. Peng S., Tomson T.T., Trimble C., He L., Hung C.F., and Wu T.C. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13 3 (2006) 257-265
36. Trimble C., Lin C.T., Hung C.F., Pai S., Juang J., He L., et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21 25/26 (2003) 4036-4042